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Adrenal metastases
Radosław Samsel1, Andrzej Cichocki1, Marcin Jankowski1, 2
The adrenal glands are one of the most prevalent sites for metastases from various malignancies and metastases are 
indeed the most frequent malignant tumors of the adrenals. The identification of incidental adrenal lesions, of which 
a high proportion are metastases, have increased since surveillance protocols in cancer treated patients were widely 
introduced. More sensitive and reliable methods of diagnostic imaging leads to earlier detection of adrenal metastases. 
If there are no signs and symptoms of disseminated malignant disease, it is essential to differentiate adrenal lesions. 
CT imaging diagnostics and MRI play the main role in differential diagnosis. Adrenal biopsy is not recommended and 
is of limited diagnostic value. Appropriate selection of patients with adrenal metastases for curative treatment is a 
great challenge. Hormonal evaluation should be performed prior to treatment. Adrenalectomy seems to be a reaso-
nable treatment for isolated adrenal metastasis in suitable patients. Minimally invasive laparoscopic adrenalectomy 
is as effective as the open approach with proven reduction in postoperative pain, morbidity and length of stay. Non-
surgical treatment such as stereotactic body radiation therapy (SBRT), radiotherapy with CyberKnife, percutaneous 
radiofrequency ablation, percutaneous microwave ablation, radiofrequency plus chemoembolization combined, 
have been reported with curative and palliative intent and have shown varied results. 
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Introduction
The adrenal glands is one of the most prevalent sites 
for metastases from various malignancies. The most com-
mon types of adrenal tumors are benign cortical adenomas 
[1], however metastases are the most frequent malignant 
tumors of the adrenal gland. The existence of adrenal meta-
stases in patients with a history of cancer varies in different 
series between 10 and 27% [2, 3]. Probably the reason for 
this frequently observed metastatic localization of various 
cancers is the rich sinusoidal blood supply of adrenal glands 
which favor this location for metastases [3]. Although most 
adrenal metastases are undoubtedly of hematogenous ori-
gin, it seems that they may develop via lymphatic spread 
from the lung [4]. Lymphatic drainage between the lung and 
the retroperitoneum is well described and some ipsilateral 
adrenal metastases may come by a lymphatic pathway, 
therefore they may be considered more as locally advanced 
than distant metastases [5]. 
Surveillance protocols in cancer treated patients have 
increased the identification of incidental adrenal lesions, 
a high proportion of which are metastases. More sensi-
tive and reliable methods of diagnostic imaging lead to 
earlier detection of adrenal metastases. In most cases it is 
part of disseminated disease; however, if isolated adrenal 
metastases are detected and removed surgically, this can 
provide an opportunity to improve the prognosis in selected 
patients [6, 7].
Selection of patients with adrenal metastases for curati-
ve treatment is a great challenge. The presence of an adrenal 
mass is reported in 1–4% patients undergoing imaging stu-
dies for various reasons [8]. The prevalence of such findings 
increases with age [9, 10]. The majority of these tumors 
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are benign nonfunctional lesions. On the other hand, the 
frequency of adrenal metastases is high. However, usually 
they are an element of generalized disease, therefore such 
patients are rather candidates for systemic chemotherapy 
or palliative supportive care. In opposition to these data, 
number of adrenalectomies performed to treat metastases 
is very low from less than one performed in a surgical center 
per year [11], up to less than six a year [12, 13]. This is one 
of the reasons that makes it difficult to establish criteria to 
define which patients will benefit from adrenalectomy in 
terms of cure or increased survival. Data available in literatu-
re are heterogeneous and differ in the frequency of tumors 
that metastasize to the adrenals. These differences in the 
prevalence of different cancers to the adrenals depend on 
the author and the geographic origin. There is only scarce 
prospective data and a lack of randomized evidence to 
confirm that local therapy on the adrenal metastases alters 
the natural course of disease. Treatment of patients with 
adrenal metastases varies among institutions and is highly 
dependent on clinical discretion.
The benefits of adrenalectomy for metastases are still 
unclear but several retrospective studies have identified 
highly selected groups of patients with lung cancer, renal 
cell cancer and melanoma whose survival seems to be pro-
longed with surgery [11, 14, 15].
Diagnosis
Incidentally detected adrenal masses in patients with no 
known malignancy occur in 5% of all abdominal computed 
tomography (CT) examinations [16]. This incidence increases 
in patients with a known underlying malignancy to 9% 
[17]. With the adrenal mass of size larger than 4 cm which 
grows on follow up imaging within 1 year, the likelihood of 
a metastatic character is up to 71% [18]. Characteristics of 
suspicious mass include: large size (especially bigger than 
4 cm) irregular contour, heterogeneous appearance and 
a temporal increase in size. 
Essential diagnostic imaging of adrenals is CT, perfor-
med before and after i.v. contrast injection. It can detect 
adrenal masses larger than 5mm in diameter. Approxima-
tely 70% of adenomas can be identified using CT with no 
contrast enhancement. The remaining 30% of adenomas 
are lipid poor and are difficult to differentiate with this tech-
nique [19].
On unenhanced CT, lipid poor adenomas have a native 
density not greater than 10 Hounsfield units (HU), and in 
clinical practice 10 HU is the most widely used threshold 
attenuation value for the diagnosis of lipid-rich adrenal ade-
noma with a sensitivity and specificity of 89% and 100% re-
spectively [20]. Malignant lesions and pheochromocytomas 
are usually lipid poor, although clear cell renal carcinoma 
metastasis, adrenal carcinoma and some pheochromocy-
tomas may be lipid rich [21]. Characterization of adrenal 
masses using contrast enhanced CT takes the advantage of 
the specific perfusion pattern of adenomas, they enhance 
rapidly after contrast administration and demonstrate a ra-
pid loss of contrast medium. This phenomenon is called 
“contrast enhancement washout”. Malignant lesions inclu-
ding metastases enhance rapidly but demonstrate a slower 
washout of contrast medium [22]. The contrast enhanced 
CT value is the attenuation value of the mass, measured 
in HU 60 s after intravenous contrast administration. The 
delayed attenuation is measured 10 or 15 min after con-
trast administration. Calculation of the absolute washout 
requires a Hounsfield value from unenhanced CT; relative 
contrast washout is calculated using 60 s and delayed va-
lues. An absolute contrast washout of > 60% and a relative 
contrast washout of > 40% characterize an adenoma with 
a sensitivity and specificity of 98 and 92% respectively [23].
Magnetic resonance imaging (MRI) of the adrenals sho-
uld include T1 and T2 weighted images and chemical shift 
imaging (CSI). A normal adrenal gland has T1 and T2 signal 
intensity equal tp or slightly lower than that of the normal 
liver [24]. Malignant tumors of the adrenal glands, including 
metastases in general, have a higher fluid content than 
adenomas and therefore are of higher signal intensity on 
T2-weighted images than the surrounding normal adrenal 
gland. After gadolinium enhancement, 90% of adenomas 
demonstrate homogenous or ring enhancement, while 60% 
of malignant masses have heterogeneous enhancement 
[25]. 
Chemical shift imaging is based on the fact that within 
a magnetic field, protons in water molecules oscillate at 
a different frequency than the protons in lipid molecules. 
Lipid rich adenomas lose signal intensity on out-of-phase 
images, compared with in-phase images, whereas malignant 
lesions that lack intracellular lipid remain unchanged. The 
combination of spin-echo signal characteristics, gadolinium 
enhancement and CSI has up to 90% accuracy in distingu-
ishing between adenomas and non-adenomas [26]. 
Whole body positron emission tomography (PET) with 
[18F] fluorodeoxyglucose ([18F]FDG) demonstrates high sen-
sitivity in detecting adrenal malignant lesions, with spe-
cificity ranging between 87 and 97%. A small number of 
adenomas and other benign lesions may mimic malignant 
lesions in PET [27]. Standardized uptake values (SUVs) of 
2.68–3.0, differentiate malignant from benign adrenal mas-
ses. The ratio of SUV of the adrenal mass and that of the 
liver of 1.45, helps to distinguish malignant adrenal lesions 
from adenomas with a sensitivity of 100% and a specificity 
of 88%. Combined FDG-PET and CT data, including contrast 
washout characteristics, have a sensitivity and specificity of 
100% and 98% respectively. 
False positive results for malignancy in PET/CT occur 
in 3–13% of adrenal lesions and include adenomas, phe-
ochromocytomas, inflammatory and infectious lesions. False 
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negatives for malignancy have been reported in adrenal 
metastases with hemorrhage or necrosis, small (5–10 mm) 
and metastases from pulmonary bronchioloalveoral carci-
noma or carcinoid tumors [28].
The biggest advantage of PET CT is the ability to di-
stinguish localized or oligometastatic disease potentially 
curable by surgery from patients with disseminated cancer 
to be treated by systemic chemotherapy or supportive care. 
It is important to remember that PET is not reliable for iden-
tifying brain metastases and another brain imaging study, 
CT or preferentially MRI, should be performed, especially in 
cases of adrenal metastases from lung cancer. 
Collision tumors
The term collision tumor refers to independently co-
existing neoplasms with different behavioral, genetic, and 
histological features that are sharply demarcated and lack 
significant tissue mixture. In contrast to composite tumors 
which arise from a common neoplastic source, collision 
tumors arise from different neoplastic sources [29]. Many 
adrenal collision tumors remain undetected due to their 
small size. All of them are a diagnostic challenge, and tumors 
should always be evaluated separately as they may repre-
sent different types. Collision tumor should be suspected 
in a patient with a history of malignancy with the imaging 
revealing a heterogeneous adrenal mass. The most common 
adrenal collision tumors are adenomas with metastases like 
renal cell carcinoma or breast cancer [30, 31].
Adrenal biopsy 
In general, adrenal biopsy is not recommended [32]. The 
only exception to this rule is suspicion of adrenal metastases 
if the expected findings are likely to alter the treatment of 
the individual patient. Data obtained from the literature 
are inconsistent. It is an invasive, expensive procedure with 
a potential for non-diagnostic results and complications. 
There have been a number of cases when biopsy did not 
alter clinical treatment of any of the patients who had un-
dergone biopsy [33].
On the other hand, there are data from a relatively large 
number of patients proving that when used in the appro-
priate clinical setting, adrenal biopsy is a powerful tool in 
the diagnostic algorithm of the evaluation of adrenal masses 
with features suspicious for malignancy [34].
The present meta-analysis of adrenal biopsies diagnostic 
performance collected data from 32 studies [35]. Informa-
tion from 2190 adrenal biopsies were analyzed. Pathology 
was reported only in 74% of cases, of which 51% (828) were 
classified as malignant. Of the malignant lesions, the majo-
rity were metastases — 83%. The most common primary 
tumors were: lung (67.3%), kidney (7.6%), melanoma (3%), 
liver, breast and colon (2.3%), esophagus (2.1%), bladder 
(1.2%) and pancreas (1%).
The pooled non-diagnostic rate was 8.7% and pooled 
overall complication rate was 2.5%. Major complications 
included adrenal hematoma, pancreatitis, pneumothorax, 
hemothorax, perirenal hematoma, duodenal hematoma 
and hypertensive crisis. In one case, needle track metastases 
seeding occurred. Worth noting is that the rate of adverse 
events may be as high as 13.6% [36, 37]. It is very important 
to remember that inadvertent biopsy of pheochromocy-
tomas can provoke ejection of catecholamines that may 
lead to severe life threatening adverse events. Endocrine 
evaluation, or at least screening with metanephrines, should 
be standard of care before the adrenal biopsy. 
The sensitivity and specificity for diagnosis of metastases 
was 87% and 96% respectively. 
Surgical treatment
The first report of adrenalectomy for adrenal metastases 
was published in 1982, describing the cases of two patients 
with long-term survival after resection of adrenal metastases 
from non-small cell lung cancer [38]. Further investigations 
demonstrated that resection of adrenal metastases from 
non-small cell cancer provided essentially longer survival 
compared to a conservative treatment [39].
So far, all the available data are from retrospective stu-
dies and there is high bias in the selection of candidates for 
adrenalectomy when comparing operated and non-opera-
ted patients. It should be remembered that adrenalectomy 
for metastasis is an infrequently performed procedure, even 
in specialized centers, and may not exceed 1 adrenalectomy 
per center per year [11]. The majority of the studies data 
are pooled from patients undergoing resection of adrenal 
metastases of all origins, whereas some studies focus on 
metastases from a single origin.
On pooling patient data, the three most common prima-
ry histologies were lung cancer (small and non-small), renal 
cell carcinoma and melanoma, representing 32%, 22% and 
15% of patients respectively [40]. In another large series, 
the most frequent primary tumors were lung (46.6%), co-
lorectal (13.5%), renal cell carcinoma (11.7%), breast (3.5%) 
and melanoma (3.5%) [6]. The relative prevalence of each 
primary malignant tumor varies according to the source of 
data and the geographic origin. Data from Asia reported a 
high prevalence of stomach (14%), esophagus (12%) and 
the liver/bile ducts cancers (10%) with a paucity of breast 
cancer and melanoma [41].
Patients considered for surgical treatment should fulfil 
such criteria as achieved control of extra adrenal disease, 
metastasis confined to the adrenal gland, performed bio-
chemical evaluation of the tumor, diagnostic imaging that 
is highly suggestive of metastasis and appears resectable, 
patient performance status warranting a surgical approach 
[42].
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Most reports indicate that surgical treatment of adrenal 
metastases may have an important therapeutic value in se-
lected patients, but no predictive factors have been clearly 
identified yet, and conclusions sometimes are contradictory. 
The median survival of patients with surgically removed 
adrenal metastases was significantly better than the survi-
val rates of patients without surgery, achieving 34 months 
versus 6 months respectively [43].
30 months median overall survival in patients with sur-
gically removed adrenal metastases was reported in another 
paper with 1-, 3- and 5-year survival of 79%, 45% and 31% 
respectively. Patients with a lung primary had significantly 
shorter survival, with median survival of 17 months and 
5-year survival of 27%, compared to patients with other
primary cancers who had a median survival of 47 months
and 5-year survival of 38%. Patients with synchronous me-
tastasis had significantly shorter survival than those who
presented metachronous lesions, with median survival of
14 vs 41 months, and 5-year survival of 21% vs 34%. Patients 
who had DFI < 12 months had worse outcomes compared 
to those with DFI > 12 months, with median survival of 13
vs 41 months and 5-year survival of 0% vs 39% [44].
In a multicenter study which assessed the results of 
adrenalectomy for solid cancer metastases in 317 patients, 
median overall survival for the whole cohort was 29 mon-
ths. Survival at 1, 2 and 5 years was 80%, 60% and 35.4% 
respectively. Significant differences in the median survival 
time according to the type of the primary tumor were ob-
served. Patients with renal cancer showed a better survival 
(median 84 months) compared with non-small lung cancer 
(median 26 months), those with colorectal cancer (median 
29 months) and those with other tumor types (median 24 
months). Patients with metachronous adrenal metastatic 
disease showed a median survival of 30 months compa-
red with 23 months in patients with synchronous adrenal 
metastases [11].
Primary renal cancer seems to have the best prognosis in 
comparison to other primary cancers. In 41 patients, overall 
median survival was 14 months and 5 years survival were 
observed in 21%, for patients with primary renal, 5 years 
survival rate was 50% [45]. Significant differences in survival 
with regard to tumor type were seen in another report, with 
longer survival for patients with colorectal carcinoma or 
renal cell carcinoma and shorter for those with non-small 
lung cancer or melanoma [46]. Not only renal primary but 
also a tumor size smaller than 5 cm in multivariate analysis 
were independently associated with longer survival in series 
of 65 consecutive patients submitted to adrenalectomy for 
metastatic disease [47].
The findings of other studies are ambiguous regarding 
factors which determinate survival after adrenalectomy for 
metastases. In a group of 90 patients with dominant primary 
melanoma and lung cancer and actual 5-year survival of 
26.2%, there was no statistically significant difference in 
overall survival for those who underwent adrenalectomy 
for metastases from lung cancer compared with those with 
melanoma or another tumor [48].
The disease free interval (DFI), defined as the time when 
the patient is tumor-free prior to recognition of adrenal 
metastasis, is a prognostic factor related to more favorable 
outcomes in patients with adrenal metastases. A DFI > 6 
months for lung cancer and > 12 months for melanoma is 
identified as an advantageous prognostic factor [49, 50].
Decreased overall survival was observed in patients with 
adrenal capsule disruption during surgery [51]. 
The reported effect of the primary tumor size in pro-
gnosing the outcome is controversial but appears to have 
some influence on survival [12, 52].
Previous metastasis surgery is a significant independent 
risk factor for worse prognosis with a hazard ratio of 5.8 in 
multivariate analysis [46]. 
Laparoscopy
Since first reported laparoscopic adrenalectomy in 
1992 [53], this minimally invasive method has become 
the procedure of choice for resection of benign tumors 
of the adrenal glands [54]. The first report of laparoscopic 
adrenalectomy for malignancy was published in 1999 [55]. 
Like in other cancer surgeries, the critical issue is whether 
laparoscopic adrenalectomy can be considered equivalent 
to open surgery in terms of recurrence rates and survival 
time. Comparing results of open and laparoscopic adre-
nalectomy is difficult because usually the compared gro-
ups are small and analyzed retrospectively. Laparoscopic 
procedure is usually reserved for tumors not larger than 
6 cm but it can be successfully performed even in tumors 
larger than 8 cm [56, 57].
The advantages of laparoscopic adrenalectomy are si-
gnificantly less blood loss, a lower complication rate, and 
shorter length of hospitalization with no difference in su-
rvival between laparoscopy and open adrenalectomy [58].
Regarding long term oncological outcomes, analysis of 
31 laparoscopic adrenalectomies and 63 open procedures 
showed similar results. Comparable rates of positive margins 
(22% vs 29%), local recurrence (11% vs 21%), and overall 
survival (median 31 months vs 30 months), were at a mean 
follow up of 42 months. The laparoscopic group experienced 
shorter operative time, lower estimated blood loss, shorter 
length of stay and fewer complications [59].
Tumor size, like in open surgery, has no influence on 
patient survival except for patients with metastases of co-
lorectal cancer. Survival for the patients with small (< 6 cm) 
size tumors was significantly better than for those with 
large tumors [12].
Conversion rates vary from 2.7% [58] to 15.6% [13], and 
complication rates from 8.3% [57] to 18.1% [12]. 
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Most of the described laparoscopic procedures were 
carried out by the lateral transperitoneal approach, but the 
posterior retroperitoneal approach may be also performed 
successfully [60], but there are data that show that retrope-
ritoneal approach may be connected with a higher risk of 
unfavorable surgical outcomes [13].
Despite promising results, open surgery is still indicated 
for large tumors (larger than 6–8 cm), when preoperative 
imaging shows local invasion or discontinuous disease [61].
At present, the size of adrenal metastasis, the absence 
of extra adrenal invasion on imaging, the biology of the 
disease, and the performance status of the patient are the 
key factors that should indicate surgical removal by a la-
paroscopic approach which seems to be currently the first 
surgical option [57].
Nonsurgical treatment
Stereotactic body radiation therapy (SBRT) refers to 
the administration of large doses of highly conformal ra-
diation with step dose gradients towards the surrounding 
normal tissue over a limited number of fractions. Over the 
past several years, there has been increasing interest in the 
use of SBRT for the treatment of adrenal gland metastases. 
Review of ten studies including 188 patients reveals that 
1-year local control ranged from 44 to 100%, and 1-year
overall survival ranged from 39.7 to 90% [62]. Overall survival 
was mainly influenced by the development of widespread 
distant metastases. Patients with metachronous metastasis 
(with a disease-free interval > 6 months), when compared
to the whole study population, showed an unimproved
2-year overall survival of 55.6%, and median survival of 44.3 
months. The toxicity of such treatment is limited to grade
2, with nausea and fatigue most commonly reported in up 
to 30–50% of patients. 
In a more recent study, results of SBRT in ten patients 
with adrenal metastases were presented. Dose and frac-
tion were determined on the basis of tumor size; patients 
received a total dose of 30 to 48 Gy in 3 to 5 doses. All of 
the patients received chemotherapy before or after SBRT. 
Median overall survival was 9.9 months. 90% of patients 
achieved control of treated adrenal gland metastasis with 
one patient experiencing progression of the adrenal gland 
metastasis 18.2 months after completion of treatment [63].
Radiotherapy with CyberNife robotic radiosurgery treat-
ment is also used to treat metastases to the adrenals. Data 
from 23 patients were analyzed retrospectively. 19 of 23 pa-
tients achieved single-fraction radiosurgery with a median 
dose of 22 Gy and four were treated in three fractions with 
a median dose of 13.5 Gy. During follow-up (median time 
23.6 months), local relapse was observed in 17% of patients 
with a mean time of 19 months to tumor progression [64].
Other methods of local control such as percutaneous 
radiofrequency ablation [65], percutaneous microwave 
ablation [66], radiofrequency plus chemoembolization 
combined [67], have been incidentally reported with small 
number of patients and limited value.
Miscellaneous
The adrenal glands may be occasionally the site of in-
volvement in patients presenting with unknown primary 
cancer (5.8%). Isolated adrenal involvement is extremely rare 
(0.2%). Patients with unknown primary cancer and adrenal 
involvement had a poor overall prognosis, with a median 
survival of only 7 months [68].
Adrenal insufficiency in patients with bilateral adrenal 
metastases or unilateral adrenal metastases in patients with 
contralateral adrenalectomy is infrequent. It develops only 
in patients with large bilateral metastases with destruction 
of more than 90% of the adrenal cortex [69]. In a large 
retrospective study including 464 patients with adrenal 
metastases from various tumors, only five (1.1%) developed 
adrenal insufficiency [41]. In oncological patients, adrenal 
insufficiency may go unrecognized because the symptoms 
such as nausea, vomiting, weakness, orthostatic hypoten-
sion and laboratory anomalies such as hyponatremia and 
hyperkalemia may be linked to the underlying disease or 
to the cancer therapy. 
Summary
There is no strong randomized evidence supporting 
the use of any adrenal metastasis therapy for improvement 
of survival in patients with limited disease. Treatment of 
such patients should be individualized under the care of 
a multidisciplinary team. Surgical treatment may be safe 
and effective in patients with metastasis isolated to the 
adrenal glands. When extra adrenal disease control is achie-
ved, diagnostic imaging is highly suggestive of metastasis 
and actual patients performance status warrants a surgical 
procedure, complete hormonal evaluation, or at least phe-
ochromocytoma exclusion, should be performed. Laparo-
scopy may be considered as a feasible and oncologically 
safe approach in selected patients.
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